Three Complete Responses in Azer-Cel Allogeneic CD19 CAR T Ph 1b Trial in DLBCL announced September 10, 2024
Three Community Cancer Centers Activated as First Sites for the Pivotal Ph 2 ALPHA3 Trial of Cemacabtagene Ansegedleucel (cema-cel) as 1L Consolidation Treatment for Patients with LBCL July 9, 2024
Odronextamab Recommended for EU Approval by the CHMP to Treat R/R Follicular Lymphoma and DLBCL July 1, 2024
Pivotal Ph 2 Trial of Cemacabtagene Ansegedleucel (cema-cel) as 1L Treatment in Large B-Cell Lymphoma (LBCL) patients initiated June 25, 2024
Enrollment in Part 2 dose expansion initiated in LOTIS-7 Trial of ZYNLONTA® + Glofitamab or Mosunetuzumab in Patients with R/R B-cell NHL April 9, 2024
FDA issued CRLs for the BLAs for odronextamab in R/R follicular lymphoma (FL) and in R/R DLBCL, each after two or more lines of systemic therapy March 26, 2024
Clinical Efficacy of Enitociclib in Combination with Venetoclax and Prednisone in Lymphoma announced January 10, 2024
Odronextamab BLA for Treatment of R/R Follicular Lymphoma (FL) and DLBCL Accepted for FDA Priority Review October 3, 2023
Ryvu Therapeutics’ Global Licensee Menarini to Expand Development of MEN1703 (SEL24) with a New Study in Advanced Diffuse Large B-Cell Lymphoma (DLBCL) September 19, 2023
Ph 2 LOTIS-9 Trial of ZYNLONTA (loncastuximab tesirine-lpyl) and Rituximab in Unfit/Frail 1L DLBCL Patients to be discontinued August 2, 2023
Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with R/R DLBCL July 27, 2023
Voluntary Pause of Enrollment in Ph 2 LOTIS-9 Trial of ZYNLONTA (loncastuximab tesirine-lpyl) and Rituximab in Unfit/Frail 1L DLBCL Patients Announced July 19, 2023
European Commission approves fixed-duration Columvi (glofitamab) for people with R/R DLBCL July 19, 2023
Expansion of NX-2127 Phase 1b Trial in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma Indications initiated June 21, 2023
CHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with R/R DLBCL May 10, 2023
